How Gilead's and Merck's Surprise Partnership Will Shake Up the HIV Market

Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) have historically been rivals in the HIV drug market. Now, though, the big companies are teaming up to develop a long-acting HIV therapy. In this Motley Fool Live video recorded on March 17, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how Gilead and Merck's surprise partnership could shake up the HIV drug market.

Continue reading

Source Fool.com